Skip to main content
. 2016 Nov 30;30(12):1165–1180. doi: 10.1177/0269881116675512

Figure 5.

Figure 5.

Percentage of participants with anti-depressant or anxiolytic response rates and anti-depressant symptom remission.

Percentages of participants in each treatment group who met criteria for anti-depressant or anxiolytic response or anti-depressant symptom remission (BDI, HAD D) at 1 day post-dose 1 (psilocybin first n=14, niacin first n=15), 7 weeks post-dose 1 (psilocybin first n=12, niacin first n=14) and at 26 weeks post-dose 2 (psilocybin first n=11, niacin first n=12). Asterisks indicate significance level of between-group comparisons at each time point.